NCT03528902View on ClinicalTrials.gov

Tamoxifen Therapy to Treat Pulmonary Arterial Hypertension

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 1, 2018

Primary Completion Date

June 14, 2023

Study Completion Date

June 14, 2023

Conditions

HypertensionPulmonary Arterial HypertensionFamilial Primary Pulmonary HypertensionPrimary Pulmonary HypertensionLung DiseasesTamoxifenEstrogen Receptor AntagonistHormone AntagonistsEstrogens

Interventions

DRUG

Tamoxifen

Tamoxifen 20 mg po daily for 24 weeks.

DRUG

Placebo Oral Tablet

Placebo

Trial Locations (1)

37232

Vanderbilt University Medical Center, Nashville

All Listed Sponsors

lead

Vanderbilt University Medical Center

OTHER

NCT03528902 - Tamoxifen Therapy to Treat Pulmonary Arterial Hypertension | Biotech Hunter | Biotech Hunter